Mutations in SCN2A cause epilepsy syndromes of variable severity including neonatal-infantile seizures. In one case, we previously described additional childhood-onset episodic ataxia. Here, we corroborate and detail the latter phenotype in three further cases. We describe the clinical characteristics, identify the causative SCN2A mutations and determine their functional consequences using whole-cell patch-clamping in mammalian cells. In total, four probands presented with neonatal-onset seizures remitting after five to 13 months. In early childhood, they started to experience repeated episodes of ataxia, accompanied in part by headache or backpain lasting minutes to several hours. In two of the new cases, we detected the novel mutation p.Arg1882Gly. While this mutation occurred de novo in both patients, one of them carries an additional known variant on the same SCN2A allele, inherited from the unaffected father (p.Gly1522Ala). Whereas p.Arg1882Gly alone shifted the activation curve by -4 mV, the combination of both variants did not affect activation, but caused a depolarizing shift of voltage-dependent inactivation, and a significant increase in Na + current density and protein production. p.Gly1522Ala alone did not change channel gating. The third new proband carries the same de novo SCN2A gain-of-function mutation as our first published case (p.Ala263Val). Our findings broaden the clinical spectrum observed with SCN2A gain-of-function mutations, showing that fairly different biophysical mechanisms can cause a convergent clinical phenotype of neonatal seizures and later onset episodic ataxia.
Introduction Gene discovery in epilepsy and related neurological syndromes, such as migraine, paroxysmal dyskinesia and episodic ataxia, has revealed that mutations in ion channels, transporters, or synaptic proteins play a crucial role in their pathophysiology [1] [2] [3] . These mutations affect the excitability of different neuronal subtypes and compartments. The altered excitability, sometimes provoked by typical decompensating triggers, episodically induces a dysfunction of neuronal networks in distinct brain regions thereby causing well-defined paroxysmal clinical symptoms. Beside 'pure' syndromes with only one characteristic clinical feature, several overlap syndromes with epilepsy as a core phenotype have been described [4, 5] .
The neuronal voltage-gated Na + channel NaV1.2, encoded by the SCN2A gene, is mutated in benign familial neonatalinfantile seizures (BFNIS), an autosomal dominant epilepsy syndrome characterized by transient seizures in the first weeks or months of life [6, 7] . These mutations mainly lead to gain-of-function defects causing neuronal hyperexcitability [8, 7] . More severe, non-familial phenotypes with neonatal onset seizures caused by de novo SCN2A mutations are increasingly described [9] [10] [11] [12] [13] [14] . One loss-of-function mutation causes epileptic encephalopathy with later onset [15] .
We previously described a single patient with neonatal-onset, relatively severe epilepsy resolving at 13 months of age, with episodes of ataxia, myoclonus and pain starting at 18 months of age. We identified a de novo missense mutation in SCN2A showing a gain-of-function defect [3] . Here, we describe three further independent cases with neonatal-onset seizures and episodic ataxia starting in early childhood. We reveal the common clinical features, the underlying SCN2A mutations and their pathophysiological mechanisms.
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Materials and methods
Patients
Clinical evaluation of the first new case (patient #1) and follow-up of the previously described one (#4) were performed in Helsinki. The other two new patients were examined at the University Clinic Giessen (patient #2) or at the Epilepsy Center Kork (patient #3). All patients were selected from routine clinical presentations in the respective centers and underwent subsequent genetic testing due to clinical suspicion of an SCN2A defect, since they presented highly similarly as case #4.
Molecular Genetics
Patient #1 underwent direct (Sanger) sequencing of SCN2A. For patients #2 and #3 an epilepsy gene panel screening was performed as reported previously [16] . Confirmation of the mutations and segregation was performed by Sanger sequencing. Long range PCR was used to determine if the two variants detected in patient #2 were on the same allele.
For SCN2A sequencing genomic DNA was isolated from EDTA-blood. The coding exons and exon-intron boundaries of SCN2A in patients #2 and #3, and mutation-carrying exons in their parents, were amplified (primers available upon request primers are available upon request) for the G1522A and G1522A + R1882G mutations. Before used in experiments, the mutant cDNA was fully resequenced to verify the introduced mutations and exclude any additional sequence alterations.
GlaxoSmithKline (Brentford, UK) kindly provided the human Na + channel subunits hβ1 and hβ2 in the pCLH vector. The hygromycin coding region in the vector was exchanged with the sequence coding for either enhanced green fluorescent protein (EGFP) or CD8 marker genes to obtain pCLH-hβ1-EGFP and pCLH-hβ2-CD8 [3, 17] .   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 5
Transfection and expression in tsA201 cells
Human tsA201 cells were cultured at 37°C, with 5% CO2 humidified atmosphere and grown in 89% Dulbecco's 
Electrophysiology
Standard whole-cell patch clamp recordings were performed using an Axopatch 200B amplifier, a Digidata 1320A digitizer and pCLAMP 8 data acquisition software (Axon Instruments, Union City, CA, USA), as has been described before [7] . Leakage and capacitive currents were automatically subtracted using a pre-pulse protocol (-P/4). Currents were filtered at 5 kHz and digitized at 20 kHz. Cells were visualized using an inverted microscope (Axio-Vert.A1; Zeiss). All recordings were performed at room temperature of 21-23°C. Na + currents of 1-12 nA were recorded from transfected tsA201 cells 10 min after establishing the whole cell configuration. Borosilicate glass pipettes had a final tip resistance of 1-2 MΩ when filled with internal recording solution (see below). We carefully checked that the maximal Voltage clamp protocols and data analysis: The activation curve (conductance-voltage relationship) was derived from the current-voltage relationship obtained by plotting the peak current over various step depolarizations (7.5 mV steps from a holding potential of -140 mV) according to
with g being the conductance, I the recorded peak current at test potential V, and Vrev the apparent observed Na + reversal potential.
The voltage-dependence of activation was fit with the following Boltzmann function:
with g being the conductance, I the recorded current amplitude at test potential V, Vrev the Na + reversal potential, gmax the maximal conductance, V1/2 the voltage of half-maximal activation and kV a slope factor. Steady-state inactivation was determined using 300 ms conditioning pulses to various potentials followed by the test pulse to -20 mV at which the peak current reflected the percentage of non-inactivated channels. A standard Boltzmann function was fit to the inactivation curves:
with I being the recorded current amplitude at the conditioning potential V, Imax being the maximal current amplitude, V1/2 the voltage of half-maximal inactivation and kV a slope factor. For analysis of the time constants of fast inactivation, the cell membrane was depolarized to various test potentials from a holding potential of -140 mV to record Na + currents.
A second-order exponential function was best fit to the time course of fast inactivation during the first 70 ms after onset of the depolarization, yielding two time constants. The weight of the second slower time constant was relatively small.
Only the fast time constant, named τh, was therefore used for data presentation in the 'Results' section. Persistent Na + currents (ISS, for the 'steady-state' current) were determined at the end of depolarizing pulses, lasting 95 ms, to different test potentials and are given relative to the initial peak current (IPEAK). Recovery from fast inactivation was recorded from holding potentials of -140 mV. Cells were depolarized to -20 mV for 100 ms to inactivate all Na + channels and then repolarized to various recovery potentials (-80, -100 or -120 mV) for increasing duration. A second-order exponential 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 7 function with an initial delay was best fit to the time course of recovery from inactivation. The faster time constant with the much larger relative amplitude, τrec, is shown for data evaluation.
Data and statistical analysis
Traces were displayed off-line with Clampfit software of pClamp 10.0 (Axon Instruments). Graphics were generated using a combination of Microsoft Excel (Microsoft Corporation, Redmond, WA, USA), and Origin (version 6.1;
OriginLab Inc., Northampton, MA, USA) software, statistics were performed using SigmaStat 3.1 (Statcon). All data were tested for normal distribution. For statistical evaluation t-test was used for comparing two groups. For comparing more than two groups, ANOVA on ranks (Kruskal-Wallis-Test) with Dunn's posthoc test for not normally distributed data or one-way ANOVA (Bonferroni posthoc test) was used when data sets were normally distributed. All data are shown as means ± SEM, "n" gives the number of cells. For all statistical tests, significance with respect to control is indicated on the figures using the following symbols: *p<0.05, **p<0.01, ***p<0.001 .   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 8
Results
Clinical characterization.
All four identified patients showed very similar phenotypes with neonatal-onset focal or generalized seizures remitting almost completely at 5-13 months old, followed by episodes of ataxia at least once a month starting in early childhood.
All clinical data are summarized in Table 1 and more detailed case descriptions are given in Online Resource 1.
Epileptic seizures in patient #1 ( Fig. 1a ), carrying only the novel de novo missense mutation p.Arg1882Gly (R1882G) started at two days old with bilateral tonic-clonic seizures with reduced oxygen saturation and unresponsiveness. The seizures were initially pharmacoresistant to phenobarbitone (PB) and valproate (VPA) but stopped by five months of age with no recurrences. Since the age of 3.7 years, episodes with slurred speech, ataxia, nausea and headache occur 1-2 times per month lasting minutes to hours. In patient #2, who carries both R1882G and also the inherited variant p.Gly1522Ala (G1522A), multifocal clonic and tonic-clonic seizures lasting 10-120 seconds occurred in the fourth week of life, and were well controlled by PB. The girl's further course was uncomplicated until a series of generalized tonicclonic seizures during a febrile infection at five months old. PB was changed to VPA and no further seizures occurred after the age of 5 months, also after VPA was finally discontinued at 7 years old. From 20 months of age on, episodes characterized by headache, slurred speech, impaired balance and ataxic gait occurred 1-10 times per week lasting 1-5 minutes.
Patient #3 (Fig. 1c ), carrying the same de novo missense SCN2A mutation as the previously described patient #4 [3] (p.Ala263Val, A263V), presented immediately after birth with a marked muscular hypotonia and sleepiness. His development was slightly retarded. A first cluster of bilateral tonic seizures occurred at 7 days of life which was resistant to different medications (see Table 1 ). Oxcarbazepine (OXC) and levetiracetam (LEV) were started at 4 months of age, and the patient remained seizure-free so far from 7 months on. At 22 months, the parents reported an episode of ataxia with mild symptoms starting in the morning and inability to walk or stand in the afternoon. Further similar attacks with ataxic gait occurred since then every 10 to 14 days, lasting hours to one day. Formerly described patient #4 presented with neonatal-onset seizures with hypomotor semiology followed by tonic-clonic seizures as described previously [3] .
During treatment with phenytoin (PHT), seizures became much less frequent at the age of 13 months. Since then, he has only suffered from three isolated generalized tonic-clonic seizures at the age of 3.5, 6.5 and 14.5 years. The habitual headache-ataxia episodes started at 18 months old and were pharmacoresistant [3] until now.
Episodic ataxia in all four patients responded poorly to any of the medications tried so far (see Table 1 , Online Resource 1 and discussion). 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   9 Genetics. In both patients #1 and #2 we identified the novel missense mutation c.5644C>G, p.Arg1882Gly (R1882G; GeneBank NM_021007.2, NC_000002.11). Sequencing of the parents revealed that the mutation occurred de novo in both patients. In addition, the missense variant c.4565G>C, p.Gly1522Ala (G1522A; rs147522594) was identified in patient #2. Rs147522594 was also detected in the healthy father ( Fig. 1c ) and occurs with an allele frequency of 0.00073% (allele count: 89/121922) within the Exome Aggregation Consortium (ExAC). Both G1522 and R1882 are completely conserved in all other 28 studied vertebrates (www.1000genomes.org). R1882G is not known to be present in Diagnostic gene panel sequencing was performed in patient #3 [16] . The same mutation (c.788C>T, p.Ala263Val) as previously described in patient #4 was detected in SCN2A [3] . Sequencing of both parents revealed that the mutation occurred de novo Functional studies. Electrophysiological analysis was first performed for the wild type (WT) channel in comparison with the de novo R1882G mutant, which was detected as the only SCN2A mutation in patient #1 (Fig 2) . This analysis revealed a significant hyperpolarizing shift of the activation curve for mutant channels (Fig. 2d ). We did not find significant differences for any other recorded gating parameter including current density (Fig. 2 , Table 2 , Online Resource 1 Fig. S1 ).
Since patient #2 carries both the de novo R1882G mutation and the inherited variant G1522A on the same allele, we additionally analyzed mutant channels carrying (i) G1522A alone, and (ii) both G1522A and R1882G (Fig. 3 ). Mutant G1522A alone did not reveal any significant changes compared to WT channels. Interestingly, the double mutant channel did not show changes of the activation curve ( Fig. 3e ), as described above for R1882G alone. In contrast, the most prominent effect for the double mutation was a 1.7-fold increase in current density compared to the other three clones, i.e. WT, G1522A and R1882G alone (Fig. 3d , Table 2 ). In addition, we found a significant shift of the steadystate fast inactivation curve towards more depolarized potentials only for channels carrying both variants (Fig. 3 , Table   2 ). Consistent with the increase in current density (as a measure for the number of functional channels in the membrane), Western blot analysis of transfected tsA201 cells -to study the amount of protein expression-revealed that the total NaV1.2 protein amount was significantly increased only in channels carrying both variants in comparison to the WT (Fig.   4 ).
We thus found differential gain-of-function effects for NaV1.2 channels carrying either the R1882G mutation alone or both variants, R1882G and G1522A. In both cases (R1882G alone or in combination with G1522A), the changes predict an increase of membrane excitability in neurons expressing mutant NaV1.2 channels. 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 10
Discussion
We here describe patients carrying two different SCN2A mutations and comprising neonatal -onset seizures and childhood-onset episodic ataxia as the two main features. When we published the first case in 2010, it was not clear if the de novo A263V mutation in SCN2A was responsible alone for the main clinical symptoms, as migraine was a common feature in both branches of the family which could have influenced the phenotype of patient #4 [3] . Detection of a second patient (#3), with the same clinical key symptoms carrying the same mutation occurring independently de novo, now strongly suggests that this mutation is causative for both the seizures and episodic ataxia. Patients #1 and #2, carrying another de novo mutation in the same gene (in patient #2 occurring in combination with an inherited known rare polymorphism), corroborate these findings that the phenotype is caused by SCN2A gain-of-function mutations. This widens the spectrum of disorders combining epilepsy with other paroxysmal neurological symptoms such as dyskinesia or ataxia, which could be attributed to the expression of respective genes in different brain areas inducing an episodic dysfunction of neuronal networks [18] [19] [20] [21] [22] [23] .
The clinical characteristics of these patients in comparison to other SCN2A-associated syndromes are that seizures recurred more frequently and persisted longer than in typical BFNIS and that those were more difficult to treat [24] . In contrast to more severe epileptic encephalopathies [9] [10] [11] [12] [13] [14] [15] , the seizures still remitted after 5-13 months (except for few occasional later seizures in patient #4). Since drugs have been discontinued in patient #2, seizure freedom can be attributed to spontaneous remission, whereas this remains unclear in the other cases, as treatment has been continued (patients #1 and #3) or restarted after seizure relapse during a drug-free period (patient #4). Notably, seizures in patient #3 responded well to the Na + channel blocker oxcarbazepine. Attacks of episodic ataxia with onset ranging 15 months to 3.7 years of age were the most important symptom beside the seizures. Episodic headache was an additional feature occurring in all patients, although rare and uncertain in one, and could be accompanied by back pain, discomfort and vomiting. Treatment of episodic ataxia is more difficult. Patients #1 and #4 did not respond to acetazolamide. In addition, 4-aminopyridine, which works well in the clinically rather similar episodic ataxia type 2 [25, 26] , did not help patient #4. The effect of Na + channel blockers, which work very well in the clinically distinct episodic ataxia type 1 with much shorter attacks triggered by sudden movements after rest [27] [28] [29] , is not yet entirely clear in our patients.
Theoretically, this group of antiepileptic drugs should counteract a gain-of-function of SCN2A mutations. There is increasing evidence that patients with severe early-onset epilepsies due to SCN2A mutations do respond to Na + channel blockers [30] . However, network effects are difficult to predict and could influence the response to such drugsalso in a distinct way in different brain regionsas shown recently for the hippocampus [31].
Our previous and the here presented electrophysiological data clearly indicate that different gain-of-function effects of the detected mutations in SCN2A cause the clinical phenotype. Whereas the A263V mutation causes mainly an increased 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 11 persistent Na + current [3] , the de novo mutation R1882G found in patient #1 showed a hyperpolarizing shift of the activation curve. In contrast, the combination of both variants in the same channel subunit, as detected in patient #2, leads to a prominent increase in current density, confirmed by a larger amount of produced protein, and a depolarizing shift of the steady-state inactivation curve (but no shift of the activation curve). Until now, many BFNIS-associated SCN2A mutationspartly showing other gain-of-function mechanismsrather exhibited a decrease in current density or cell surface expression, which however rarely reached statistical significance [3, 7, 17, 32] . This confirms the peculiar importance of the increased current density of the combined variants found in patient #2. All observed effects predict an increased Na + inflow and a neuronal hyperexcitability, which can explain the dysfunction of cortical or cerebellar networks causing the clinical symptoms of our patients.
We have previously suggested that the age-dependent occurrence of seizures and remission in BFNIS could be due to the high NaV1.2 channel expression in axon initial segments of hippocampal and cortical pyramidal neurons early in development and their partial replacement by NaV1.6 channels with increasing maturation [7] . This mechanism could also contribute to seizure remission in the additional three cases. Although the episodic ataxia found in the studied patients might have many different causes, one hypothesis for later onset ataxia could be due to a delayed upregulation of NaV1.2 in cerebellar granule cells [7, 33] .
Interestingly, different substitutions of the arginine at position 1882 (R1882Q and R1882L) have been identified in two de novo cases exhibiting epileptic encephalopathy [11] and intractable seizures, optic atrophy, severe intellectual disability, brain abnormalities and muscular hypotonia [13] . Furthermore, the A263V mutation has also been described as occurring de novo in monozygotic twins with Ohtahara syndrome and other unique neuropathologic abnormalities [34] , and a A263T mutation has been identified in a patient with a different type of early-onset epileptic encephalopathy [12] . These observations indicate that not only the mutation determines the clinical phenotype, but that other factors such as the genetic background have to play a role in genotype-phenotype relationships.
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Figure legends
Representative experiment illustrating total NaV1.2 protein expression of tsA201 cells transfected with: only transfection reagent as Mock control, WT-NaV1.2, only G1522A, only R1882G or both G1522A/R1882G and detected with anti-pan sodium channel antibody. The immunoreactive bands of Mock-control, NaV1.2-WT or mutant proteins were normalized to the amount of the endogenous membrane-cytoskeletal protein Vinculin. (b) Quantification of six independent experiments by normalizing the signals of NaV1.2 protein bands to the corresponding Vinculin signals in total lysates demonstrated that each mutation exposed a higher level of Na + channel expression, but only G1522A/R1882G presented a significant increase of the expression level compared to the WT (**p<0.01; N=6, one way ANOVA with Bonferroni posthoc test). All values are shown as mean ± SEM   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 
